The industrial biotechnology company evoxx technologies GmbH has become a part of the leading specialty biotech company Advanced Enzyme Technologies Limited. Both companies announced on August 1 that they have entered into a binding agreement about the acquisition of 100% stake in evoxx technologies.

Evoxx is merger of two German biotech companies

Evoxx is a spin-off of the university of Düsseldorf and operating under the name evocatal since 2016. As an industrial biotechnology company, a main focus was on the development and production of industrial enzymes for the food health & wellness sector and consumer products markets. The new company name “evoxx” came with the merger with Potsdam-based carbohydrate specialist aevotis. The team of 35+ scientists & technicians across the two sites in Germany, Monheim am Rhein and Potsdam, will now represent the Research & Development centers and sales points of Advanced Enzymes in Europe.

Largest manufacturer of enzymes in Central Asia

The chairman of Advanced Enzymes, V.L. Rathi, said: “evoxx has a great strategic fit for us. With evoxx we significantly expand our R&D capabilities and also strengthen our European presence.” The Indian enzyme giant said the acquisition will give Advanced Enzymes a stronger foothold in Germany and in Europe and will also help strengthen its Research & Development capabilities. The acquisition will also help Advanced Enzymes expand its enzyme portfolio & business in biocatalysis and food applications.

“Together with the strong partners in India and USA, the portfolio of industrial enzymes will be larger and more attractive for the existing and future customers of evoxx. Furthermore, the production plants and production knowledge of Advanced Enzymes will help evoxx deliver enzymes in industrial scale,” said Thorsten Eggert, CEO of evoxx technologies.

evoxx underlined that it will ensure continuity in cooperative projects with customers and partners. The proprietary technology platform of evoxx technologies to develop tailor-made enzymes and processes for various industries will be still available in the future. The High-Tech Gründerfonds (HTGF), a long-term investor of evoxx, was pleased about the exit.

pg